Implication of the genetic polymorphism of the Catecolamin Transferasa gene in response to treatment of patients with major depression.

The study of the involvement of genetic polymorphisms in the catechol-O-methyltransferase (COMT) gene in the treatment response of patients with major depressive disorder aims to determine whether specific genetic variants may influence the efficacy and clinical response to antidepressant treatment. By characterizing COMT gene polymorphisms and correlating them with clinical and therapeutic variables, the study seeks to identify potential associations between patients’ genetic profiles and treatment response, contributing to a better understanding of the genetic factors underlying variability in therapeutic outcomes and supporting the development of more personalized treatment strategies.